Trial Profile
Intravitreal Ranibizumab in Patients With Retinal Pigment Epithelial Detachments Secondary to Age-related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Jan 2018
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- Acronyms RECOVER
- 18 Jan 2018 New trial record